AP
HUMA icon

Antipodes Partners’s Humacyte HUMA Stock Holding History

Antipodes Partners’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.88M Buy
10,103,647
+4,379,897
+77% +$4.06M 0.14% 65
2026
Q1 		$3.47M Buy
5,723,750
+5,712,102
+49,039% +$5.94M 0.07% 59
2025
Q4 		$11.2K Buy
11,648
+3,523
+43% +$4.99K ﹤0.01% 128
2025
Q3 		$14.1K Buy
8,125
+951
+13% +$1.86K ﹤0.01% 112
2025
Q2 		$15K Buy
+7,174
New +$13.8K ﹤0.01% 102

Other funds holding HUMA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Antipodes Partners's HUMA Position: Q2 2026 in Review

Antipodes Partners increased its Humacyte (HUMA) stake by 77% in Q2 2026, buying an estimated $4.06M and bringing the position to 10,103,647 shares worth $7.88M. The position accounts for 0.14% of the portfolio, ranked #65.

Antipodes Partners first reported a position in HUMA in Q2 2025 and has held it in 5 quarters since. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Antipodes Partners held 10,103,647 shares of Humacyte worth $7.88M as of Q2 2026.
  • Antipodes Partners bought 4,379,897 Humacyte shares in Q2 2026, an estimated $4.06M.
  • Humacyte made up 0.14% of Antipodes Partners's portfolio in Q2 2026, its #65 holding.
  • Antipodes Partners first reported a position in Humacyte in Q2 2025 and has held it in 5 quarters since.
  • 161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.